Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate whether Vyvanse, a psychostimulant, can
help children ages 6-16 with attention deficits due to traumatic brain injury (TBI). Vyvanse
is currently approved for the treatment of Attention-Deficit/Hyperactivity (ADHD). The exact
effects this drug may have on adults with attention deficits caused by TBI have been
investigated prior. The exact effects this drug may have on children with attention deficits
caused by TBI are not known, but the investigators expect that Vyvanse will be of some help
in treating this population as well.